{"efta_number": "EFTA01919360", "page_count": 3, "url": "https://epstein-data.com/EFTA01919360", "pdf_url": "https://epstein-data.com/pdf/EFTA01919360.pdf", "pages": [{"efta_number": "EFTA01919360", "page_number": 0, "text_content": "6/24/2014 \nJ.E. Invoice: \nI. Exome sequencing: This is $1000 each. Right now I only have JE's saliva sample for \nsequencing. If he wants to submit the kits I provided him with, it will be $1000 for each \nadditional sample. \n= $1000 (+ $1000 for every additional exome for other people submitting saliva samples) \n2. Exome sequencing of JE's fibroblasts:  I discussed with JE the research significance of \ncomparing his exome data on blood with his fibroblast cell lines (which I already have \nfrozen down in liquid nitro at Boston Childrens Hospital). Sequencing this cell line would \nbe an additional $1000. \nI'm going to try my best to get it in with this sequencing run but because they are cells, \nthat may be tricky. (They'll get in the next round if they don't make this one.) \n= $1000 \n3. iPS cell lines:  We've discussed making adult stem cells from JE's fibroblast cells. If we do \nthis, he, like George Church, would be one of very few people in the world to have this \ndone. With multiple cell passages, the process takes a minimum of 6 months and there's \nno guarantee it will work — but the failure rate is probably around 1 in 6 or less and eve in \nthose instances, we can still do it — it would just take more time and some additional funds \nfor reagents. \nPrice = $10,000. This is pretty much at cost given the labor and reagents. I only know of 1 \ncommercial group providing this service — and they charge more than $10,000/ induced \npluripotent cell line. \n= $10,000 \n4. Whole genome sequencing through Illumina' I won't be able to send this on to Illumina \nuntil JE completes the second consent form which should be available in 1-2 weeks. If he \nwants to send it ahead of time though, I guess that's fine. \n= —$11,400 for rapid turnaround \nI don't know if JE's parents are living — but if he wanted to include them (which greatly \naids my genome analysis to have that data to compare), the cost would be $21,000. See: \nhttp://www.illumina.com/clinical/illumina_clinical_laboratoryngs_for doctots/how_to_ord \ncr.ilmn \nEFTA_R1_00361487 \nEFTA01919360\n", "char_count": 2068}, {"efta_number": "EFTA01919360", "page_number": 1, "text_content": "5. Whole genome analyses. We only discussed very briefly so I'm not sure Jeffrey will \nremember but I mentioned to him that I was starting a medical genomics private practice \nthat would charge for personal whole genome and exome analyses. We're planning to \nprice this in the $10,000 range per patient and will include reanalysis of genomic data \n(based on our collective improved knowledge of genomic variants) on a yearly basis for 3 \nyears. \nMy plan for the first few people to sign up is to offer longterm biobanking of DNA and \ncells and lifelong reanalysis of data. Even if we expand as planned, because of the labor \ninvolved, we would only be able to offer this for our first few patients. Essentially, I would \nbe the personal medical genomicist for these people. To my knowledge, no such service is \navailable yet. If he's interested... \n= $10,000 \n6. Personalized longevity studies:  Funding for genetics research in academia generally relies \non federal NIH funding or pharma funding — which, respectively, are disease and drug \nfocused. I'm seeking funding to systematically introduce mutations in cell culture that \nwould be expected to increase longevity. If he goes with number 5 (lifelong analyses) and \nnumber 3 above (generation of iPS cell lines from his fibros), I would bundle this work \ninto #5 and do the genomic engineering on his iPS cells when they're available. \nI would use a CRISPR/Cas9 platform to introduce the mutations. I would need the money \nfor reagents but this work would essentially be included with #5 for JE since he would be \none of the first. Since it's so labor intensive (the technology is brand new so there are no \nautomated systems to do this yet). \n= free if going with #5 + CRISPR/Cas9 reagents(this should only be a few thousand) \n7. Venus project: Jeffrey and briefly discussed a genomic research studying I'm dubbing the \nVenus project (he'll know what this). I can do this for him but doing this work would be \ngreatly aided by having some good bioinformatic infrastructure. This infrastructure could \nbe used for the Venus project, YPO analyses, and other projects. Total anticpated costs \nfor this would be $160,00: \nGenomic hardware: $100,000 \nGenomic software: $60,000/yr (this is for 2 systems costing $30,000 each/yr) \nThe software component would only need to be paid for I year because I'm confident I \ncan get other funding to cover this once we publish data in the first year using these \nresources. \n= $160,000 \nThis is a big ticket item (at least relative to my bank acct 0) so I'm happy to discuss this \nitem more with Jeffrey if he's interested in supporting this. If he covers this and pays for \nEFTA_R1_00361488 \nEFTA01919361\n", "char_count": 2698}, {"efta_number": "EFTA01919360", "page_number": 2, "text_content": "the exomes which $1000/person — and he mentioned 200 participants being in this project \n— I can deliver on this \"Venus\" research. \nSo, if he goes with everything on this invoice, it's: \nI. $1000 ($1000 for every additional exome on others he wants to include in the YPO study) \n2. $1000 for exome sequencing of JE's fibros \n3. $10,000 to create adult stem cells for JE from his fibro cell lines \n4. $11,400 for his whole genome ($21,000 if he wanted to include both of his parents; not \nsure if this is even feasible) \n5. $10,000 indefinite biobanking of his samples for eternity, lifelong reanalysis of genomic \ndata on an annual basis, and CRISPR/Cas9 manipulation of his adult stem cells to \nintroduce mutations in culture believed to increase longevity. I'm only offering this to \nJeffrey. Because of all the labor involved, there's simply not enough bandwidth to offer \nthis to more than a handful of people right now (at least in 2014). \n6. Included in #5 \n7. $160,000 Bioinformatic infrastructure for the Venus project, the YPO study, and any \nother pet genomic projects Jeffrey might have interest in now or in the future. \nTotal: $193,400.00 \nEFTA_R1_00361489 \nEFTA01919362\n", "char_count": 1184}]}